Inicio › Cáncer de mama triple negativo › Míchigan › Grand Rapids
Ensayos clínicos de Cáncer de mama triple negativo en Grand Rapids, MI
15 estudios para Cáncer de mama triple negativo buscan participantes en centros de Grand Rapids y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ReclutandoFase 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
ReclutandoFase 1/2
- BAMF Health, Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
ReclutandoFase 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
ReclutandoFase 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
ReclutandoFase 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
ReclutandoFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
ReclutandoFase 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
ReclutandoFase 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
ReclutandoFase 1
- START Midwest /ID# 248685, Grand Rapids
Ensayos de Cáncer de mama triple negativo en otras ciudades
- Houston, TX42 estudios
- New York City, NY31 estudios
- Nashville, TN27 estudios
- Los Angeles, CA26 estudios
- Boston, MA26 estudios
- San Antonio, TX22 estudios
- St. Louis, MO21 estudios
- Arlington, VA20 estudios
- Atlanta, GA20 estudios
- Dallas, TX18 estudios
- Columbus, OH16 estudios
- Chicago, IL16 estudios
Otros estudios en Grand Rapids
- Cáncer de pulmón de células no pequeñas44 estudios
- Cáncer del colon y del recto40 estudios
- Cáncer (todos los tipos)28 estudios
- Cáncer de seno26 estudios
- Cáncer de ovario24 estudios
- Cáncer metastásico22 estudios
- Cáncer de próstata19 estudios
- Cáncer de páncreas18 estudios
- Cáncer de estómago18 estudios
- Cáncer de endometrio18 estudios
- Melanoma17 estudios
- Carcinoma de células escamosas de cabeza y cuello15 estudios
De ClinicalTrials.gov, datos obtenidos el 7 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.